Bengt Sjöberg donates SEK 2 billion to cancer research

Bengt Sjöberg, resident in Hong Kong but originally from Lysekil, Sweden, has founded the Sjöberg Foundation, to which he has donated SEK 2 billion. His hope is that this donation will make a difference to cancer research and the treatment currently received by cancer patients.

"I have intended to start some form of foundation for a number of years, giving back to society through the capital I have amassed over my life. My idea is that the foundation should primarily focus on cancer research but, if the riddle of cancer is solved in the future, I would like the foundation to be able to contribute to other medical research and also to environmental research. I want the research to which I contribute to be as clinically focused as possible, so it can be applied rapidly. My hope is that the foundation will contribute to a new view of cancer treatment, in which there is equal openness to evaluating both conventional and unconventional treatment methods, as well as a combination of them both."

Bengt Sjöberg is 66 and received a diagnosis of lung cancer at the start of the year; he particularly hopes that the foundation’s money will improve lung cancer care and the treatment opportunities currently available in Sweden.

"The current survival figures for Swedish lung cancer care are depressing, and if I can be part of helping people to enjoy better quality of life and longer lives, it is worth every krona."

The foundation will award an annual Sjöberg Prize to a prominent cancer researcher or cancer research group. The prize will be awarded in close cooperation with the Royal Swedish Academy of Sciences, and the value of the prize will be equivalent to USD 1 million, of which the majority is designated for further research. In addition to the Sjöberg Prize, the foundation hopes to allocate SEK 60-70 million every year; discussions are currently underway with Karolinska Institutet in Stockholm regarding a new cancer centre. Bengt Sjöberg hopes that the foundation's money can start to be put to use in 2016.

"I am a businessman and have spent my life building companies, but this is the most rewarding thing I have done and I would like to see the results as soon as possible."

The first chair of the foundation's board is Bengt Sjöberg. Ingemar Sjöberg, Bengt Sjöberg's brother, has been appointed vice-chair and the secretary is Ola Johannesson. Other board members are Bengt Sjöberg's two children, Michelle Sjöberg and Joachim Sjöberg, as well as Göran K. Hansson and Annika Espander.

The foundation will be registered in Lysekil Municipality.

The Royal Swedish Academy of Sciences, founded in 1739, is an independent organization whose overall objective is to promote the sciences and strengthen their influence in society. The Academy takes special responsibility for the natural sciences and mathematics, but endeavours to promote the exchange of ideas between various disciplines.

Most Popular Now

Therapy using dual immune system cells effectively…

A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was ...

How to develop new drugs based on merged datasets

Polymorphs are molecules that have different molecular packing arrangements despite identical chemical compositions. In a recent paper, researchers at GlaxoSmithKline (GS...

New drug combination effective against SARS-CoV-2 …

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the wo...

Cleveland Clinic study suggests steroid nasal spra…

A recent Cleveland Clinic study found that patients who regularly use steroid nasal sprays are less likely to develop severe COVID-19-related disease, including a 20 to 2...

Sanofi to focus its COVID-19 development efforts o…

Recent positive interim results of Sanofi's mRNA-based COVID-19 vaccine candidate Phase 1/2 study confirm the company's platform robust capabilities and strategy in mRNA...

Discovery of mechanics of drug targets for COVID-1…

A team of international researchers, including McGill Professor Stéphane Laporte, have discovered the working mechanism of potential drug targets for various diseases suc...

Phase II/III trial shows Ronapreve™ (casirivimab a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive data from the phase II/III 2066 study, investigating Ronapreve™ (casirivimab and imdevimab) in patients hospit...

Pfizer and BioNTech receive first U.S. FDA Emergen…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use a booster dose of the P...

AZD7442 request for Emergency Use Authorization fo…

AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) com...

Pfizer and BioNTech receive CHMP positive opinion …

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the Europea...

Boehringer Ingelheim acquires Abexxa Biologics to …

Boehringer Ingelheim announced the acquisition of Abexxa Biologics Inc., a biopharmaceutical company taking a new approach in the fields of immuno-oncology and oncology r...

GSK welcomes WHO recommendation for broad roll-out…

GlaxoSmithKline (GSK) plc welcomes and applauds the WHO recommendation for the broader deployment of GSK's RTS,S malaria vaccine to reduce childhood illness and deaths fr...